Neuronetics (STIM) Announces Proposed Public Offering of Common Stock
Get Alerts STIM Hot Sheet
Join SI Premium – FREE
Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it has commenced an underwritten public offering of its common stock. The Company intends to grant the underwriters a 30-day option to purchase an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares to be sold in the proposed offering will be sold by the Company.
The Company currently intends to use the net proceeds from this offering for general corporate purposes, including working capital, research and development, marketing and evaluating new clinical indications.
Piper Sandler & Co. and William Blair & Company, L.L.C. are acting as joint book-running managers for the offering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- INmune Bio (INMB) Prices 572K Share Offering at $8.32/sh
- Volato (SOAR) Files for Share Offering
Create E-mail Alert Related Categories
Corporate News, Equity OfferingsRelated Entities
William Blair, S3, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!